FIELD: cellular immunotherapy.
SUBSTANCE: invention relates to a composition for expanding lymphocyte, a method of producing a population of clinically significant lymphocytes, to a method of treating or preventing diseases in a mammal (versions), to using a kit in immunotherapy, to a clinically significant lymphocyte (versions), to a population of clinically significant lymphocytes (versions). Composition for lymphocyte expansion contains interleukin-2 (IL-2), interleukin-15 (IL-15) and interleukin-21 (IL-21) in certain concentrations, wherein the composition is in a liquid form. Method for producing a population of clinically significant lymphocytes involves a number of steps: obtaining a tissue sample or body fluid sample, body in vitro culture of the sample for expansion and/or stimulation of lymphocytes in the sample, wherein the culturing involves using IL-2, IL-15 and IL-21 taken in certain concentrations, determining the presence of a clinically significant lymphocyte in the cultured sample. Method of treating or preventing a malignant disease in a mammal, involving certain stages. Method of treating or preventing an infectious disease in a mammal, involving certain stages. Method of treating or preventing an autoimmune disease in a mammal, involving certain stages. Use of kit in immunotherapy, where kit contains IL-2, IL-15 and IL-21, taken in certain concentrations, in liquid composition, a component which stimulates TCR-costimulatory molecules, feeder cells and a peptide comprising a sequence of at least one clinically significant antigen. Clinically significant lymphocyte obtained by said method (versions). Population of clinically significant lymphocytes obtained by the above method (versions).
EFFECT: described above enables to ensure successful expansion of lymphocytes against a variety of different tumors due to the developed agents and methods for obtaining a product of expanded lymphocytes with improved composition of T-cell phenotypes for effective ACT applicable for other types of tumors.
38 cl, 18 tbl, 42 ex, 33 dwg
Title | Year | Author | Number |
---|---|---|---|
OBTAINING ANTIGEN-SPECIFIC T-CELLS | 2017 |
|
RU2745319C2 |
METHOD AND COMPOSITIONS FOR CELLULAR IMMUNOTHERAPY | 2012 |
|
RU2688185C2 |
METHOD OF OBTAINING A CULTURE OF LYMPHOCYTES ENRICHED IN TUMOR-SPECIFIC T-LYMPHOCYTE CLONES AND CELL CULTURES OBTAINED USING THE SPECIFIED METHOD | 2022 |
|
RU2808595C1 |
PRODUCTS OF A CERTAIN COMPOSITION CONTAINING GENETICALLY MODIFIED T CELLS | 2015 |
|
RU2751921C2 |
METHOD FOR ASSESSING THE SENSITIVITY OF A TUMOR TO IMMUNO-ONCOLOGICAL DRUGS | 2021 |
|
RU2771760C1 |
METHODS FOR PRODUCTION OF COMPOSITIONS OF GENETICALLY ENGINEERED CELLS AND RELATED COMPOSITIONS | 2018 |
|
RU2790444C2 |
IMPROVED METHOD FOR INCREASING TUMOUR-RESPONSIVE T-LYMPHOCYTE COUNT IN IMMUNOTHERAPY OF ONCOLOGIC PATIENTS | 2006 |
|
RU2399382C2 |
METHOD OF PRODUCTION OF T-CELLS | 2015 |
|
RU2813668C2 |
VETO-CELLS OBTAINED FROM MEMORY T-CELLS | 2017 |
|
RU2779844C2 |
METHOD OF PREDICTING THE DEVELOPMENT OF METASTASES IN PATIENTS WITH UNRESECTABLE TRIPLE-NEGATIVE BREAST CANCER | 2023 |
|
RU2802141C1 |
Authors
Dates
2020-12-28—Published
2015-06-11—Filed